Brief: NGM Bio Announces Initiation Of Phase 1/1B Clinical Trial Of Ngm831 For The Treatment Of Patients With Advanced Solid Tumors
31/03/2022 21:55
March 31 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO ANNOUNCES INITIATION OF PHASE 1/1B CLINICAL TRIAL
OF
NGM831 FOR THE TREATMENT OF PATIENTS WITH ADVANCED SOLID TUMORS
Source text for Eikon: ID:nGNX8YxL6k
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors